InnovAge Holding Corp. — Form 10-Q Summary
Reporting period: The supplied filing is for the quarter ended March 31, 2021, with year-to-date results for the nine months ended March 31, 2021. This differs from the request metadata identifying 2020 Q3. Amounts below are in U.S. dollars; financial statement amounts are generally in millions.
Business context
InnovAge operates a single reportable PACE segment, providing comprehensive, capitated care to frail seniors. It served approximately 6,655 participants through 18 centers in five states at March 31, 2021. The company bears the risk for participants’ healthcare costs and receives payments primarily from Medicare and Medicaid. It completed its IPO in March 2021.
Financial results and liquidity
| Metric | Three months ended March 31, 2021 | Nine months ended March 31, 2021 | Prior-year comparable |
|---|---|---|---|
| Total revenue | $156.3 million | $466.2 million | $144.8 million and $414.7 million |
| Operating income (loss) | $(5.4) million | $(23.0) million | $13.0 million and $30.8 million |
| Net income (loss) attributable to InnovAge | $(10.5) million | $(50.5) million | $8.1 million and $14.2 million |
| Adjusted EBITDA, non-GAAP | $20.3 million | $66.0 million | $17.6 million and $43.0 million |
| Operating cash flow | Not separately presented | $(17.0) million | $20.0 million provided |
- Revenue rose 8% for the quarter and 12% year to date, primarily from increased participant census and rates. Management also cited the temporary suspension of Medicare sequestration as a revenue benefit.
- For the nine-month period, center-level contribution margin was 27.0% of revenue versus 23.1% a year earlier. Adjusted EBITDA margin was 14.2% versus 10.4%. These are non-GAAP measures; they exclude specified items and are not substitutes for GAAP results.
- Cash and cash equivalents were $201.5 million at March 31, 2021, with restricted cash of $2.2 million. Cash, cash equivalents and restricted cash totaled $203.8 million. Current assets were $251.9 million and current liabilities $94.0 million.
- Debt principal was approximately $77.4 million, comprising a $75.0 million term loan and $2.4 million convertible loan. The $100.0 million revolving facility was undrawn. The company reported covenant compliance.
- Year-to-date investing cash outflow was $16.1 million, including $14.1 million of property and equipment purchases. Financing provided $122.3 million, including $373.6 million of IPO proceeds, offset by debt repayments and other transaction payments.
Material changes and unusual items
- GAAP results were affected by transaction-related and other nonrecurring items. Year-to-date corporate, general and administrative expense was $105.9 million, including $42.2 million related to cancellation of prior stock options and $13.1 million of Apax transaction costs; IPO-related costs also contributed.
- The company recorded a $13.5 million quarterly loss on extinguishment of debt, including a $6.0 million prepayment fee, as it replaced its prior credit agreement alongside the IPO. The year-to-date debt-extinguishment loss was $14.5 million.
- InnovAge Sacramento became consolidated on January 1, 2021, producing a one-time $10.9 million gain on remeasurement of the prior equity-method investment and adding $8.1 million of goodwill.
- A $20.0 million contingent consideration payment related to the New Courtland acquisition was triggered by the IPO. The filing reports significant other operating expense associated with contingent-consideration changes and payment.
- The IPO issued 18,995,901 shares at $21.00 per share and generated $373.6 million in net proceeds. Proceeds, together with new credit-agreement borrowings, were used to repay the former credit facility, cover related fees and fund the New Courtland earn-out.
- Year-to-date operating cash flow turned negative, chiefly reflecting the reported loss and transaction-related expenses; increases in amounts due to Medicare and Medicaid partly offset cash uses.
Outlook, commentary and risks
- Management said cash and operating cash flows should be sufficient for at least the next 12 months, while noting that actual capital needs depend on growth, center openings and other factors. It expects to retain funds and does not anticipate cash dividends in the foreseeable future.
- Management intends to pursue enrollment growth, expansion within existing centers, selective new centers and acquisitions. It expects expenses to rise in absolute dollars, including public-company costs, and said near-term investment may increase expenses as a percentage of revenue.
- COVID-19 shifted care toward in-home and telehealth settings. The filing reported no revenue decline attributed to the pandemic through March 31, 2021, but said future effects are uncertain. Reduced ability to document participant conditions could lower Medicare risk-adjustment scores and future revenue; delayed care could also raise later costs.
- The company disclosed that certain centers had not timely completed some required new-participant assessments and care plans. It is working to remedy the issue; failure to meet requirements could result in enrollment restrictions or other regulatory consequences.
- Other material exposures include bearing full healthcare-cost risk, medical-cost estimation, staffing shortages and labor costs, government reimbursement and regulatory changes, and possible recoupment or audit of COVID-related assistance. Management said ordinary-course litigation was not expected to materially affect the company; no legal proceedings were listed in Part II.
- The company reported effective disclosure controls as of March 31, 2021 and no material quarter-on-quarter change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the applicable reporting period: the filing covers March 31, 2021, not 2020 Q3.
- Assess how much of the GAAP loss and cash-flow deterioration reflects one-time transaction items versus recurring operating performance; review the company’s non-GAAP reconciliations.
- Track census growth, participant acuity and Medicare risk-adjustment documentation, particularly as pandemic-related care practices evolve.
- Monitor remediation of late assessments and care plans, and any resulting regulatory or enrollment actions.
- Review medical-cost trends, Medicaid/Medicare settlements and working-capital movements, alongside liquidity and compliance with credit-agreement covenants.